Cargando…

WU and KI polyomavirus infections in pediatric hematology/oncology patients with acute respiratory tract illness

BACKGROUND: WU and KI polyomaviruses (PyV) were discovered in 2007 in respiratory tract samples in adults and children. Other polyomaviruses (BKPyV and JCPyV) have been associated with illness in immunocompromised patients, and some studies suggest a higher prevalence of WUPyV and KIPyV in this popu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Suchitra, Garcea, Robert L., Robinson, Christine C., Simões, Eric A.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816538/
https://www.ncbi.nlm.nih.gov/pubmed/21705268
http://dx.doi.org/10.1016/j.jcv.2011.05.024
Descripción
Sumario:BACKGROUND: WU and KI polyomaviruses (PyV) were discovered in 2007 in respiratory tract samples in adults and children. Other polyomaviruses (BKPyV and JCPyV) have been associated with illness in immunocompromised patients, and some studies suggest a higher prevalence of WUPyV and KIPyV in this population. OBJECTIVE: To determine whether a higher prevalence or viral load for WUPyV and KIPyV exists in immunocompromised children compared with immunocompetent children. STUDY DESIGN: We measured the prevalence and viral load of WU and KI PyV by quantitative real-time PCR of viral DNA in respiratory tract specimens from pediatric hematology/oncology patients and immunocompetent controls with acute respiratory illnesses. RESULTS: The prevalence of WUPyV in the immunocompromised population was 5/161 (3%) versus 14/295 (5%) in the control population (P = 0.5), and 9/161 (5.6%) versus 7/295 (2.3%) respectively for KIPyV (P = 0.13). The mean viral load (in copies per cell or mL of sample) for KIPyV, was higher in the immunocompromised group compared to the control group (P = 0.019), but was not statistically different for WUPyV. A higher prevalence was seen in the hematopoietic stem cell transplant recipients compared with other immunocompromised patients (6/26 versus 3/43, P = 0.054). Viral persistence was demonstrated only in 1/25 (4%) of sequential samples for KIPyV, and no persistence was seen for WUPyV. CONCLUSIONS: A higher prevalence of WUPyV or KIPyV in the immunocompromised population compared with the immunocompetent group was not demonstrated. Higher viral loads for KIPyV in the immunocompromised group may suggest an increased pathogenic potential in this population.